Planning for success with an allogeneic Treg cell sourcing strategy

Cell & Gene Therapy Insights 2024; 10(4), 579–585

DOI: 10.18609/cgti.2024.070

Published: 23 May
Matthew Breton

Autologous Treg cell therapy products have shown promise in early clinical studies, but obstacles related to scalability and adoption have hindered their commercial viability. David McCall, Senior Editor, BioInsights, speaks with Matthew Breton, Director, Process Development and Manufacturing, Tr1X, about overcoming these challenges by following the allogeneic pathway.